Status:
TERMINATED
Omega 6:Omega 3 Ratio and Progression of Age-related Macular Degeneration (AMD).
Lead Sponsor:
Yves Sauve
Collaborating Sponsors:
Canadian Institutes of Health Research (CIHR)
Conditions:
Age-related Macular Degeneration
Eligibility:
All Genders
50+ years
Brief Summary
Docosahexaenoic acid (DHA) supplementation has been shown to prevent specific age-related changes in the retina through biochemical and functional evaluations, but it is unclear whether increased DHA ...
Eligibility Criteria
Inclusion
- 50+ years of age
- NVAMD (Wet) in one eye, early or intermediate dry-AMD in the fellow eye
- taking AREDS vitamins (or equivalent)
Exclusion
- Central geographic atrophy
- Diabetic retinopathy
- Ocular surgery in the eye with dry-AMD (not including cataract IOL surgery)
- Underlying ocular pathology in the eye with dry-AMD (especially glaucoma, dense cataracts, and retinitis pigmentosa)
Key Trial Info
Start Date :
March 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2014
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00987129
Start Date
March 1 2012
End Date
December 1 2014
Last Update
January 6 2015
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Alberta Retina Consultants
Edmonton, Alberta, Canada, T5H 0X5
2
Royal Alexandra Hospital
Edmonton, Alberta, Canada, T5H 3V9
3
University of Alberta
Edmonton, Alberta, Canada, T6G 2H7